The AGM is a few days away. Perhaps the most near term inflection point is the sample size re-estimation analysis (SSRA). Results and announcement of the BETonMACE SSRA, if it happens, is expected any day now. Positive SSRA results can confirm that the current enrollment, number of target MACE and projected trial length are all unchanged. It would also time stamp that 188 adjudicated events have occurred. However, SSRA could also recommend changes. There are three additional trials (renal FFabry disease, PAH) listed on ClinicalTrials.gov that have 2018 start dates listed but haven't started yet. Resverlogix news released end of July the intent to pursue US listing. They have amended BETonMACE to allow for longer dosing but have not issued any official statement on this or updated the ClinicalTrials.gov listing in almost a year. We're hoping for an AGM Corporate Update webcast but no official company news release on this yet. 

In my opinion, the price movement this past week was due to anticipation, narrowing bookends, and hope for clarity to conquer the uncertainty. Resverlogix has a huge opportunity to build on this momentum with the proper timing and content of news in the near term. However, little to no new info soon could be a momentum killer.

What kind of cards are they holding and how close to their chest are they going to continue to hold them? In my opinion, the formal clarification of the SSRA plan this week and the results of the potential SSRA are the most important inflection points in the next month.

BearDownAZ